Mumbai: Pharmaceutical firm Glenmark today said it has received the US administration’s approval for marketing Ranitidine tablets, used to treat and prevent ulcers.
The company through its subsidiary Glenmark Generics has received Abbreviated New Drug Application (ANDA) approval from US Food and Drug Administration, Glenmark said in a filing to the Bombay Stock Exchange.
“This recent approval will be the third product added to the US subsidiary’s product portfolio within this month of November alone,” Glenmark Generics Chief Executive Officer Terrance Coughlin said.
Further, Coughlin added GGI has already completed two launches earlier this month as well as Azathioprine Tablets 50mg, the company said.
Glenmark Generics will soon commence marketing and distribution of these products in the US market, the filing added.
The firm’s current portfolio consists of 37 generic products authorised for distribution in the US market. The company company currently has 40 ANDA’s filed with the US FDA pending approval, the filing added.
Glenmark was trading at Rs315.60, up 2.87% on the BSE.